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Summary
Objective: To investigate the effects of growth and differentiation factor-5 (GDF-5) alone or in combination with insulin on engineered cartilage
from primary or expanded chondrocytes during 3-dimensional in vitro culture.
Design: Juvenile bovine chondrocytes were seeded either as primary or as expanded (passage 2) cells onto polyglycolic acid ﬁber meshes
and cultured for 3 weeks in vitro. Additionally, adult human chondrocytes were grown in pellet culture after expansion (passage 2). The culture
medium was supplemented either with GDF-5 in varying concentrations or insulin alone, or with combinations thereof.
Results: For primary chondrocytes, the combination of GDF-5 and insulin led to increased proliferation and construct weight, as compared to
either factor alone, however, the production of glycosaminoglycans (GAG) and collagen per cell were not affected. With expanded bovine
chondrocytes, the use of GDF-5 or insulin alone led to only very small constructs with no type II collagen detectable. However, the combination
of GDF-5 (0.01 or 0.1 mg/ml) and insulin (2.5 mg/ml) yielded cartilaginous constructs and, in contrast to the primary cells, the observed redif-
ferentiating effects were elicited on the cellular level independent of proliferation (increased production of GAG and collagen per cell, clear shift
in collagen subtype expression with type II collagen observed throughout the construct). The synergistic redifferentiating effects of the GDF-5/
insulin combination were conﬁrmed with expanded adult human cells, also exhibiting a clear shift in collagen subtype expression on the mRNA
and protein level.
Conclusions: In combination with insulin, GDF-5 appears to enable the redifferentiation of expanded chondrocytes and the concurrent
generation of cartilaginous constructs. The demonstration of these synergistic effects also for adult human chondrocytes supports the clinical
relevance of the ﬁndings.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Engineering of articular cartilage represents a promising,
though challenging therapeutic option, especially for larger
defects in the joint1,2. The limited source of harvestable
autologous chondrocytes represents one major limiting fac-
tor for engineering of cartilage substitutes. An approach to
overcome this problem consists in the prior proliferation of
harvested cells in a 2-dimensional culture. Afterwards the
expanded cells are seeded on a 3-D cell carrier and are
further cultivated. However, proliferation in 2-D culture com-
monly results in cell dedifferentiation rendering the cells less
suitable for tissue engineering purposes2,3. In order to1This work was performed at the Department of Pharmaceutical
Technology, University of Regensburg, Regensburg, Germany.
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1503nevertheless be able to employ this valuable cell source, it
is of major importance to establish means of redifferentiation
of the expanded chondrocytes. One approach to improve
engineered cartilage constructs is the application of growth
factors, either during cell expansion4e7 or during tissue
construct development4,7e9. The aim of this study was to elu-
cidate the potential of the protein growth and differentiation
factor-5 (GDF-5) to improve tissue construct development
either made from primary or from expanded chondrocytes,
with a clear focus on the latter, clinically more relevant cells.
GDF-5 is a member of the bone morphogenetic protein
(BMP) subfamily; BMPs in turn are members of the trans-
forming growth factor-b (TGF-b) superfamily and were orig-
inally identiﬁed as inducers of bone and cartilage formation
in vivo10. GDF-5, also known as cartilage-derived morpho-
genetic protein 1 (CDMP1), is a factor known to be involved
in limb formation11e13 and is also found in the stage of
precartilaginous mesenchymal condensation and through-
out the cartilaginous cores of the developing long bones
of bovine embryos14. It has also been postulated to be
involved in the maintenance of normal cartilage and
1504 B. Appel et al.: Synergistic effects of GDF-5 and insulinregenerative response in diseased tissue as it was found in
the superﬁcial layer of normal cartilage and throughout
osteoarthritic cartilage15.
Within this study, the effects of GDF-5 either alone or in
combination with insulin on development of engineered
cartilage were investigated. Insulin has previously been
demonstrated to have distinct anabolic effects on engi-
neered cartilaginous constructs from primary cells similar
to those of insulin-like growth factor-I (IGF-I)16,17. Employ-
ing primary and expanded juvenile bovine chondrocytes,
cell-polymer constructs were generated using polyglycolic
acid (PGA) ﬁber scaffolds as a 3-D model system that
has been previously successfully employed in cartilage en-
gineering and other tissue engineering applications16,18e20.
Additionally, expanded adult human chondrocytes were
employed in a 3-D pellet culture system which has also
been used previously for cartilage engineering21,22.
In the experiments presented here, engineered cartilage
constructs were assessed with regard to their histological
appearance and extracellular matrix (ECM) composition,
i.e., glycosaminoglycan (GAG) and collagen content. The
study demonstrates, for the juvenile bovine cells as well
as for the adult human cells, synergistic effects of GDF-5
and insulin clearly improving cartilaginous cell-polymer con-
structs made from expanded (passage 2) chondrocytes, as
compared to the effects of either factor alone.Materials and methodsCHONDROCYTE ISOLATION AND EXPANSIONThree knee joints from three-month-old bovine calves were obtained from
a local slaughterhousewithin 6e12 h of slaughter. Primary chondrocytes were
isolated from the femoral patellar groove by enzymatic digestion with collage-
nase type II (Worthington, CellSystems, St. Katharinen, Germany) as previ-
ously described16,23. For the ﬁrst study, primary chondrocytes were seeded
immediately onto PGA scaffolds (Albany International, Mansﬁeld, MA, USA;
die-punched into discs 5 mm in diameter and 2 mm thick16). For the second
study, the primary chondrocytes were expanded in monolayer (1 106 cells
per ﬂask; T150 cell culture ﬂasks; Corning, Bodenheim, Germany). Cells
were cultivated in mediumDulbecco’s Modiﬁed Eagle’s Medium (DMEM) con-
taining 4.5 g/l glucose, 584 mg/l glutamine, 10% fetal bovine serum (FBS),
50 U/ml penicillin, 50 mg/ml streptomycin, 10 mM 4-(2-hydroxyethyl)-1-pipera-
zinoethanesulfonic acid (HEPES), 0.1 mM non-essential amino acids (all from
Gibco, Karlsruhe, Germany), 0.4 mM proline, and 50 mg/ml ascorbic acid (Sig-
maeAldrich, Taufkirchen, Germany) to conﬂuence over 13 days. Subse-
quently, the cells (passage 1) were trypsinized (10-fold increase in cell
number) and seeded again in T150 cell culture ﬂasks. After 8 days they
were conﬂuent again (passage 2, ninefold increase in cell number). During
the expansion phases medium was replaced three times per week. After ex-
pansion, cells were harvested and seeded onto the PGA scaffolds.
Human cartilage explants were obtained with informed consent from pa-
tients (age of 20e55 years) undergoing reconstructive rhinoplasty (according
to approval of the local Ethics Committee, votum # 05/169). Five explants
were pooled and primary chondrocytes were obtained by digestion overnight
with collagenase type II after pre-digestion with pronase E (SigmaeAldrich,
Taufkirchen, Germany). Then primary cells were seeded in T75 culture
ﬂasks (5 105 per ﬂask) and expanded in culture medium (composition de-
scribed above) containing 10% FBS. Medium was exchanged three times
per week. After 12 days and reaching ﬁrst conﬂuency cells were trypsinized
and seeded again in T75 culture ﬂasks. After further 7 days cells were con-
ﬂuent again (P2) and harvested for pellet culture.3-D CELL CULTURE MODELFor the bovine chondrocytes (either primary or passage 2), cell seeding
was performed in spinner ﬂasks as described elsewhere16. In brief, a cell
suspension with 5 106 isolated chondrocytes per scaffold in 110 ml of cul-
ture medium was ﬁlled into the ﬂask. Flasks were placed in an incubator at
37C, 5% CO2 and 95% humidity; stirring with 50 rpm on a magnetic stirrer
for 2 days allowed for cell attachment.
Each scaffold was then placed in a well of a six-well plate ﬁlled with 6 ml of
culture medium (same medium as above except for 1% FBS instead of 10%);
plates were placed on an orbital shaker at 50 rpm (Stuart Scientiﬁc, Surrey,
UK). After 1 day, exogenous growth factors were added and from then onwith each medium change. Human growth and differentiation factor
(HuGDF-5) (Biopharm, Heidelberg, Germany) was applied at concentrations
of 0.01, 0.1, or 0.5 mg/ml and insulin (Sanoﬁ-Aventis, Frankfurt/Main, Germany)
at a single concentration of 2.5 mg/ml, which has been proven as concentration
eliciting maximum response in previous studies with insulin in this cartilage en-
gineering system16. Control constructs were cultured in medium without addi-
tional growth factor. In all groups, medium was replaced three times per week.
Four individual constructs were cultured per group over 21 days.
Pellets of human chondrocytes (passage 2) were prepared in V-bottomed
96-well plates (Nunc via Fisher Scientiﬁc GmbH, Schwerte, Germany) by
centrifugation of 2.5 105 chondrocytes suspended in 200 ml culture me-
dium (composition described above) containing 10% FBS per well for
5 min. After 24 h for pellet consolidation, growth factors were added to the
culture medium and from then on with each medium change (three times
per week). As the experiments employing the human chondrocytes were per-
formed to in principle conﬁrm the results obtained with bovine chondrocytes,
only the most important groups were cultured: HuGDF-5 at 0.1 mg/ml, insulin
at 2.5 mg/ml, and the combination of HuGDF-5 at 0.1 mg/ml and insulin at
2.5 mg/ml. Control constructs received medium without growth factor supple-
mentation. Six individual constructs were cultured per group over 21 days.ANALYSIS OF ECM CONTENT AND CELL NUMBER OF THE
ENGINEERED TISSUESAnalytical assays were performed as previously described16. In brief, cell-
polymer constructs were weighed (¼wet weight, ww) and cut in half. One
part was freeze-dried and digested by papain solution (3.2 U/ml in buffer;
Worthington, CellSystems, St. Katharinen, Germany) for 18 h at 60C.
Cell number was determined measuring the DNA content using Hoechst
33258 dye (Polysciences, Warrington, PA, USA) in a ﬂuorometrical assay24.
The sulfated GAG content was determined spectrophotometrically at
525 nm as chondroitin sulfate after reaction with dimethylmethylene blue
(SigmaeAldrich, Taufkirchen, Germany)25,26. Hydroxyproline content was
measured spectrophotometrically at 550 nm after acid hydrolysis and reac-
tion with chloramine-T and p-dimethylaminobenzaldehyde (Merck, Darm-
stadt, Germany)27. The total collagen amount was calculated using
a hydroxyproline to collagen ratio of 1:1028.HISTOLOGY OF THE ENGINEERED TISSUESThe constructs (from scaffold and pellet cultures) were ﬁxed in 2% glutaral-
dehyde for 30 min and stored in 10% formalin (Merck, Darmstadt, Germany).
After ﬁxation, the tissues were embedded in parafﬁn and sliced into 5 mm sec-
tions. The deparafﬁnized sections were subjected to a hematoxylin, fast green
and safranin-O (SigmaeAldrich, Taufkirchen, Germany) staining29.IMMUNOHISTOCHEMISTRY OF THE ENGINEERED TISSUESThe constructs made from bovine chondrocytes were ﬁxed in a mixture of
methanol/phosphate buffered saline (PBS) and 9% formaldehyde (Merck,
Darmstadt, Germany). They were incubated in ascending concentrations
of sucrose solution and frozen in Tissue-Tek for cryosectioning as previously
described30. The slides were incubated overnight with primary antibody so-
lution dissolved with PBS/tween in a ratio of 1:1000 for type I collagen anti-
body (col-1) (SigmaeAldrich, Taufkirchen, Germany) and 1:6 for type II
collagen antibody (CIIC1) [Developmental Studies Hybridoma Bank
(DSHB), University of Iowa, USA], for control sections pure PBS containing
0.1% tween-80 was used. After incubation with a secondary biotinylated an-
tibody (BA-1400 from Vector Laboratories, Linaris, Wertheim-Bettingen, Ger-
many) staining procedure was performed following the manufacturer
operating procedures using a Vectastain ABC-kit and a DAB-kit (both from
Vector Laboratories, Linaris, Wertheim-Bettingen, Germany).
Immunohistochemistry of the pellets from expanded human chondrocytes
was conducted similarly (see above), but applying tissue embedded in paraf-
ﬁn, which were deparafﬁnized before the staining procedure. The slides were
incubated overnight with primary antibody solution dissolved in a ratio of
1:500 for col-1 (SigmaeAldrich, Taufkirchen, Germany) and 1:25 for CIIC1
(DSHB, University of Iowa, USA) followed by incubation with secondary
antibody and subsequently with streptavidinehorseradish peroxidase
(HRP) (both Dako, Hamburg, Germany). Staining was performed with 3,30-
Diaminobenzidine Enhanced Liquid Substrate System (SigmaeAldrich, Tauf-
kirchen, Germany). Nuclei were counterstained with Weigert’s hematoxylin.QUANTITATIVE REAL-TIME REVERSE TRANSCRIPTION-
POLYMERASE CHAIN REACTION (RT-PCR)Pellets made from passaged human chondrocytes were subjected to RT-
PCR. RNA was extracted using RNeasy Mini Kit (Qiagen, Hilden Germany)
according to the manufacturer’s protocol. Synthesis of cDNA was conducted
Table I
Sequences of the primers applied for RT-PCR
Primer Sequence
GAPDH fw: 50-gaa ggt gaa ggt cgg agt c-30
rv: 50-gaa gat ggt gat ggg att tc-30
Col1a1 fw: 50-agg gcc aag acg aag aca tc-30
rv: 50-aga tca cgt cat cgc aca aca-30
Col2a1 fw: 50-ttc agc tat gga gat gac aat c-30
rv: 50-aga gtc cta gag tga ctg ag-30
1505Osteoarthritis and Cartilage Vol. 17, No. 11using Superscript II (Invitrogen, Karlsruhe, Germany) in the presence of
oligo-dt primers, nucleotides and ribonuclease inhibitor (Invitrogen,
Karlsruhe, Germany).
Quantitative real-time RT-PCR was performed using Platinum Sybr Green
qPCR Supermix (Invitrogen, Karlsruhe, Germany) with ABI Prism 7000
(Applied Biosciences, Darmstadt, Germany). Glyceraldehyde phosphate
dehydrogenase (GAPDH) served as housekeeping gene, to which the
expression levels of the target genes were normalized. Expression levels
were further normalized to levels of the control samples (set as 100%).
Sequences of the applied primers are given in Table I.STATISTICAL ANALYSISStatistical signiﬁcance was assessed by one-way analysis of variance
(ANOVA) in conjunction with Tukey’s studentized range test using SPSS
12 for Windows from SPSS Software (Munich, Germany).A B
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Fig. 1. Wet weight (A), cell number (BeC), GAG content (DeE), and colla
primary chondrocytes after 3 weeks of culture. Data represents the avera
ferences between the groups are denoted by symResultsBOVINE PRIMARY CHONDROCYTE CULTUREWet weight and cell number
Within 21daysof culture,GDF-5 at 0.1 mg/ml and0.5 mg/ml
increased construct wet weight 2.3-fold and 5.3-fold, respec-
tively, as compared to control; no effect was observed at
0.01 mg/ml [Fig. 1(A)]. Insulin at a concentration of 2.5 mg/ml
increased the wet weight threefold. Strikingly, in combination
with insulin, even the low concentrations of GDF-5 led to
a strong increase in wet weight (up to 7.5-fold) [Fig. 1(A)].
Similar effects were observed for absolute cell numbers
within the constructs. GDF-5 led to a dose-dependent
increase of proliferation. The combinations of GDF-5 and
insulin resulted in distinctly higher cell numbers, as compared
to either factor alone at its respective concentration [up to
a 3.9-fold increase compared to control constructs;
Fig. 1(B)]. The cell number per wet weight decreased by the
supplementation with growth factors accordingly [Fig. 1(C)].
GAG and collagen content
The GAG content in the cartilaginous constructs from
primary cells was strongly increased by the addition of sup-
plemented proteins [Fig. 1(D)]. For the GAG content per cellC 
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G 0.1 GDF-5  0.1 µg/ml
G 0.5 GDF-5  0.5 µg/ml
G 0.01+I GDF-5  0.01 µg/ml
+ Insulin  2.5 µg/ml
G 0.1+I GDF-5  0.1 µg/ml
+ Insulin  2.5 µg/ml
gen content (FeG) of cell-polymer constructs generated with bovine
geSD of four independent constructs. Statistically signiﬁcant dif-
bol (B) (P< 0.05) or asterisk (*) (P< 0.01).
1506 B. Appel et al.: Synergistic effects of GDF-5 and insulinhighest values were obtained for insulin, GDF-5 alone at the
highest concentration, and the combinations (up to 3.1-fold
increase), i.e., the combinations showed no advantage
compared to insulin alone [Fig. 1(E)]. The GAG content in
the scaffolds was also conﬁrmed histologically with strong
safranin-O staining for all growth factor receiving groups
(data not shown).
The addition of proteins affected the amount of total col-
lagen in a similar fashion as observed for GAG [Fig. 1(D,
F)]. The collagen content per cell was increased for all in-
sulin-receiving groups; again the combinations had no
advantage compared to insulin alone [Fig. 1(G)]. Immuno-
histochemical analysis demonstrated a homogeneous
staining for type II collagen throughout the whole cross-
section of all scaffolds, only at the edges all scaffolds
showed a positive staining for type I collagen (data not
shown).BOVINE PASSAGE 2 CHONDROCYTE CULTUREMacroscopic appearance, wet weight, and cell
number
Employing passage 2 chondrocytes, after a culture period
of 21 days constructs of the control group were comparably
small (Fig. 2) and had only about 16% of wet weight of pri-
mary chondrocyte control constructs [Fig. 3(A), compare
Fig. 1(A)]. Whereas insulin increased the wet weight by
2.2-fold, GDF-5 alone led to no signiﬁcant increase in wet
weight. However, in combination with insulin, GDF-5 in-
creased the wet weight by 3.2-fold (GDF-5 at 0.01 mg/ml)
and 4.8-fold (GDF-5 at 0.1 mg/ml), respectively [Fig. 3(A)].
The constructs of the latter group were the only ones that
maintained the original scaffold size (Fig. 2).Fig. 2. Macroscopic appearance of cell-polymer constructs generated wit
viations for groups: CTR: control; I2.5: insulin at 2.5 mg/ml; G: GDF-5 at 0
with insulin at 2In contrast, the absolute cell numbers were not affected for
all groups, as compared to control constructs, except for the
combination receiving insulin and GDF-5 at 0.1 mg/ml, which
showed a slight increase [1.2-fold compared to control;
Fig. 3(B)]. The cell number per wet weight decreased by the
supplementation with growth factors accordingly [Fig. 3(C)].
GAG and collagen content
In general, absolute amounts of GAG and collagen corre-
lated well with construct weights. The administration of a sin-
gle protein did not cause a signiﬁcant difference in GAG
content. However, both combinations of GDF-5 and insulin
resulted in signiﬁcant increases in absolute GAG amounts
(up to 5.7-fold) andGAGper cell (up to 3.7-fold) [Fig. 3(D, E)].
The collagen content was also not signiﬁcantly affected
by GDF-5 alone. Insulin alone increased the collagen con-
tent, but highest values were again obtained for the combi-
nations of GDF-5 and insulin, with increases in absolute
amount of collagen up to 5.3-fold and in collagen per cell
up to 3.8-fold [Fig. 3(F, G)].
Histology
The control group exhibited small constructs with large
areas of cells with a ﬁbroblastic phenotype (stained blue)
and a small core stained red for GAG with safranin-O
(Fig. 4). The addition of insulin resulted in larger constructs,
but still with large blue stained areas containing ﬁbroblastic
cells and a core with only weak GAG staining. Supplemen-
tation of GDF-5 alone resulted in an enhanced staining for
GAG in the inner region of the construct, as compared to
the control and insulin group; the blue stained areas were re-
duced to the outer regions of the scaffolds. The combinationh bovine passage 2 chondrocytes after 3 weeks of culture. Abbre-
.01, 0.1, or 0.5 mg/ml; Gþ I: GDF-5 at 0.01 or 0.1 mg/ml combined
.5 mg/ml.
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Fig. 3. Wet weight (A), cell number (BeC), GAG content (DeE), and collagen content (FeG) of cell-polymer constructs generated with bovine
passage 2 chondrocytes after 3 weeks of culture. Data represents the averageSD of four independent constructs. Statistically signiﬁcant
differences between the groups are denoted by symbol (B) (P< 0.05) or asterisk (*) (P< 0.01).
1507Osteoarthritis and Cartilage Vol. 17, No. 11of GDF-5 and insulin resulted in scaffolds with an even
stronger staining for GAG. In the combination receiving
GDF-5 at 0.1 mg/ml, GAG was distributed throughout the
constructs; small blue stained areas with ﬁbroblastic cells
could only be found on the edge of the constructs (Fig. 4).
Immunohistochemical staining
Staining for type I collagen was detected throughout the
control constructs; insulin alone led to even more intensive
staining [Fig. 5(A)]. GDF-5 alone elicited a biphasic re-
sponse: at low concentration of 0.01 mg/ml, a type I collagen
staining similar to the control constructs was observed; at
0.1 mg/ml GDF-5, a reduction of type I collagen in large
areas of the core of the construct was observed; in contrast,
at 0.5 mg/ml GDF-5, the strongest staining for type I colla-
gen of all groups was detected. Strikingly, the combination
of GDF-5 and insulin led to a distinct reduction of type I col-
lagen staining; especially in the combination GDF-5/insulin
0.1/2.5 mg/ml, there was no type I collagen detectable
throughout the construct except for a thin area at the
edge [Fig. 5(A)].
Type II collagen [Fig. 5(B)] could not be detected in con-
trol constructs and in constructs receiving either insulin or
GDF-5 alone. However, the combination GDF-5/insulin at
0.01/2.5 mg/ml showed type II collagen staining in smallareas, and at 0.1/2.5 mg/ml the combination resulted in
well-distributed staining in large areas of the constructs.HUMAN PASSAGE 2 CHONDROCYTE CULTUREMacroscopic appearance, histology and
immunohistochemical staining
The study with human P2 chondrocytes rendered similar
results compared to bovine passage 2 chondrocyte culture.
Application of proteins resulted in increased pellet size as
compared to controls. Control pellets and pellets receiving
single proteins exhibited a homogeneous, but weak safra-
nin-O staining for GAG [Fig. 6(A)]. The combination of
GDF-5 and insulin resulted in a distinctly stronger staining
for GAG in large areas of the pellet.
Control constructs were stained positive for type I collagen
[Fig. 6(B)]. Constructs cultured under supplementation with
insulin (2.5 mg/ml) or GDF-5 (0.1 mg/ml) also displayed a pos-
itive staining for type I collagen, however, staining was less
intense compared to the control group. The combined appli-
cation of GDF-5 and insulin resulted in a distinctly lighter
staining for type I collagen compared to the other experimen-
tal groups. Complementary results were observed by type II
collagen immunohistochemical staining. Neither control con-
structs nor constructs receiving either insulin or GDF-5 alone
Fig. 4. GAG distribution in cross-sections of cell-polymer constructs generated with bovine passage 2 chondrocytes after 3 weeks of culture.
GAG was stained red with safranin-O (appears dark gray in black & white print) (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.).
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der supplementation with the combination of GDF-5 and in-
sulin, a strong type II collagen staining was detected.
Quantitative real-time RT-PCR
Type I collagen mRNA was upregulated by insulin, as
compared to controls (3.6-fold), whereas it was not affected
by GDF-5 applied alone or in combination with insulin
[Fig. 7(A)]. In contrast, application of insulin alone led to
a distinct down-regulation of type II collagen mRNA expres-
sion compared to control (33-fold), and the combination of
GDF-5 and insulin resulted in a tremendous up-regulation
of type II collagen [115-fold; Fig. 7(B)].
Discussion
GDF-5 is known to play an essential role in embryonic
chondrogenesis and limb formation10,31,32. There is evi-
dence that GDF-5 takes part in the complex cascade of
bone fracture healing, for example, by playing a central
role in chondrogenesis and maturation of chondrocy-
tes33e35. In adult bovine and human cartilage, GDF-5 was
found to be expressed in both normal and osteoarthritic tis-
sue15. However, the speciﬁc functions of GDF-5 in adult
cartilage are still to be elucidated. Nevertheless, GDF-5 rep-
resents an interesting candidate molecule for cartilage engi-
neering applications, as suggested in several studies using
different in vitro and in vivo models36e39.
In engineering cartilaginous constructs, the use of in vitro
expanded chondrocytes is still one of the major obstacles. In
order to improve constructs made from passaged chondro-
cytes, different approaches have employed various growth
factors4e9. Within this study, GDF-5 has been evaluated
with regard to its ability to improve engineered cartilage con-
structs made from primary and expanded juvenile bovine as
well as expanded adult human chondrocytes in vitro.
On primary chondrocytes, GDF-5 alone elicited strong
dose-dependent effects on proliferation, total wet weight,and the ECM content of the treated constructs (Fig. 1).
When GDF-5 was combined with insulin, cell proliferation
was even enhanced, as compared to either factor alone.
The construct weight and GAG and collagen amounts
were increased in a similar fashion when the combinations
were applied. However, the ECM content expressed per cell
was not improved in the constructs receiving the combina-
tions as compared to those receiving insulin alone
(Fig. 1). Thus, it can be concluded that for the primary chon-
drocytes the increased weight and ECM amounts caused
by the combination of GDF-5 and insulin, as compared to
insulin alone, were mainly a result of the increased cell
proliferation.
In the experiments employing expanded chondrocytes,
GDF-5 alone did not signiﬁcantly affect cell proliferation,
construct weight or ECM content (Fig. 3). The fact that the
insulin group had a higher collagen content than the control
and the groups receiving only GDF-5, but similar GAG con-
tent as the other groups, may be explained in part by the im-
munohistochemical staining. It appears that insulin alone
strongly favored expression of type I collagen (Fig. 5) with
little effect on GAG synthesis. Strikingly, when applying
combinations of GDF-5 and insulin, a clear improvement
of the construct quality was achieved. In strong contrast
to the primary cells, for the expanded chondrocytes these
effects were exerted in a synergistic manner independent
of cell proliferation. This can be clearly deduced from the re-
sults obtained for the lowest GDF-5 concentration and its
combination with insulin: constructs generated with GDF-5
at 0.01 mg/ml, insulin, or the combination had the same
cell number, however, the combination resulted in in-
creases of GAG and collagen content per cell, as compared
to either factor alone (Fig. 3). Moreover, immunohistochem-
ical staining for type I and type II collagen demonstrated that
only the combination of GDF-5 and insulin evoked
redifferentiating effects indicated by a clear shift in collagen
subtype expression towards that of a more cartilaginous
phenotype: whereas type I collagen expression was
reduced by the combination, as compared to controls and
Fig. 5. Type I collagen (A) and type II collagen (B) distributions in cross-sections of cell-polymer constructs generated with bovine passage 2
chondrocytes after 3 weeks of culture. Collagens were immunohistochemically stained employing type I and type II collagen antibody, respec-
tively (brown stain, appears dark gray in black & white print) (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.).
1509Osteoarthritis and Cartilage Vol. 17, No. 11either factor alone, type II collagen expression was solely
detected in constructs generated with the combination
(Fig. 5). The results obtained with the juvenile bovine cells
were supported by experiments employing adult human
chondrocytes: again, only the combination of GDF-5 and in-
sulin led to type II collagen expression, as detected by
immunohistochemistry, at the same time reducing expres-
sion of type I collagen, compared to either factor alone
(Fig. 6). Type II collagen expression was also dramatically
upregulated for the combination at the mRNA level
(Fig. 7). Whereas no other studies on passaged chondro-
cytes employing GDF-5 are currently available, previously
it has been reported that GDF-5 stimulated the ECM re-
sponse of fetal rat calvarial cells towards the chondrogenic
phenotype40. Interestingly, in mesenchymal stem cellssupplementation of GDF-5 alone led to only a slight up-reg-
ulation of type II collagen expression and had no effect on
type I collagen, whereas a combination of GDF-5 and
TGF-b1 distinctly increased type II collagen and reduced
type I collagen expression41. In summary, in our study, nei-
ther factor alone was able to overcome the dedifferentiation
resulting from chondrocyte expansion; however, the combi-
nation of GDF-5 and insulin led to cartilaginous constructs
with cells more actively producing ECM, and with a distinctly
improved collagen subtype content.
The PGA scaffolds that were used in the 3-D model culture
with the bovine chondrocytes are known to degrade within
a few weeks of culture42. Only chondrocytes with a relatively
high synthetic activity, such as primary cells, produce enough
ECM in a short period of time to maintain the size of the
Fig. 6. Cross-sections of pellets generated with human passage 2 chondrocytes after 3 weeks of culture. GAG distribution (A), GAG was
stained red with safranin-O (appears dark gray in black & white print). Type I collagen (B) and type II collagen (C) distributions, collagens
were immunohistochemically stained employing type I and type II collagens antibody, respectively (brown stain, appears dark gray in black
& white print) (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.).
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cytes receiving the combination of GDF-5 at 0.1 mg/ml and in-
sulin; constructs in all other groups shrank to a certain extent
due to a partial breakdown of the PGA ﬁbers. (This phenome-
nonhasalsobeenpreviously described for other cell typespro-
ducing less ECM than chondrocytes43.) Apart from the PGA
scaffolds, in independent experiments using pellet cultures
(see experiments with adult human cells), very similar results
with regard to chondrocyte redifferentiation were obtained
with the combination of GDF-5 and insulin, indicating that the
synergistic effects are independent of the type of 3-D culture.
With regard to the underlying mechanisms of the beneﬁ-
cial effects of the GDF-5/insulin combination, it is striking
that there are clear differences between the primary and
the passaged chondrocyte cultures.Whereas for the primary
cells, the beneﬁcial effects on construct size, as compared to
insulin alone, were to be attributed to increased proliferation,
for the passaged chondrocytes the distinct redifferentiating
effects were elicited on the cellular level independent of pro-
liferation (increased ECM production per cell, shift in colla-
gen subtype expression on mRNA and protein level). It is
of special interest to further elucidate the mechanisms re-
sponsible for the redifferentiating effects on the passaged
chondrocytes in future studies. One possible explanation is
an up-regulation of receptor densities. GDF-5 transmits its
signals through binding to two different serine-/threonine-ki-
nase receptors, that is, type II (either activin receptor-II
(ActR-II), ActR-II´B, or bone morphogenetic protienreceptor-II (BMPR-II)) and type I (BMPR-IB)44e46, which
form a heterodimeric complex. As described for other growth
factors in skeletal development such as TGF-b1, ﬁbroblast
growth factor-2 (FGF-2), and platelet derived growth factor-
AB (PDGF-AB)41,47 insulin may induce expression of
BMPR-IB in turn enhancing the signal transduction of
GDF-5. Furthermore, there is evidence that dedifferentiated
cells pass through similar stages when redifferentiating, as
cells do in chondrogenesis22. Consequently, other possible
mechanisms for the synergistic effects include transcrip-
tional cross-talk, such as elicited by morphogens and growth
factors during chondrogenesis. In our study, cross-talk be-
tween Smad and mitogen-activated protein (MAP) kinase
pathways activated by GDF-5 and insulin may have been in-
volved in the observed effects46,48,49.
In conclusion, in the presented study, GDF-5 was dem-
onstrated to be a useful protein in cartilage engineering in
vitro. Especially in combination with insulin, GDF-5 ap-
pears to enable the redifferentiation of expanded chondro-
cytes and the concurrent generation of relevant
cartilaginous constructs. The demonstration of the syner-
gistic redifferentiating effects of GDF-5 and insulin also
for adult human chondrocytes further adds to the clinical
relevance of the ﬁndings. Moreover, the fact that GDF-5
decisively modulates the response to another cartilage-ef-
fective protein contributes to the emerging picture of the
role GDF-5 apparently plays in chondrogenesis and carti-
lage physiology.
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I 2.5 Insulin  2.5 µg/ml
G 0.1 GDF-5  0.1 µg/ml
G 0.1+I GDF-5  0.1 µg/ml
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B
Fig. 7. Relative quantiﬁcation using RT-PCR of type I collagen (A) and type II collagen (B) mRNA expression on day 21 of pellet culture with
human passage 2 chondrocytes. Data represents the average of two or three independent constructs, error bars indicate the minimum and
maximum values. Expression levels of target genes were normalized to the expression of GAPDH serving as housekeeping gene. Expression
levels were further normalized to expression levels of the control samples (set as 100%).
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